HK1095045A1 - Modified exendins and uses thereof - Google Patents

Modified exendins and uses thereof

Info

Publication number
HK1095045A1
HK1095045A1 HK07102543.1A HK07102543A HK1095045A1 HK 1095045 A1 HK1095045 A1 HK 1095045A1 HK 07102543 A HK07102543 A HK 07102543A HK 1095045 A1 HK1095045 A1 HK 1095045A1
Authority
HK
Hong Kong
Prior art keywords
modified exendins
exendins
modified
Prior art date
Application number
HK07102543.1A
Other languages
English (en)
Inventor
Aifeng Lv
Original Assignee
Wuxi Grandchamp Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Grandchamp Pharmaceutical Technology Co Ltd filed Critical Wuxi Grandchamp Pharmaceutical Technology Co Ltd
Publication of HK1095045A1 publication Critical patent/HK1095045A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK07102543.1A 2005-01-14 2007-03-08 Modified exendins and uses thereof HK1095045A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200510038102 2005-01-14
PCT/CN2006/000029 WO2006074600A1 (fr) 2005-01-14 2006-01-10 Exendines modifiees et utilisations correspondantes

Publications (1)

Publication Number Publication Date
HK1095045A1 true HK1095045A1 (en) 2007-04-20

Family

ID=36677361

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07102543.1A HK1095045A1 (en) 2005-01-14 2007-03-08 Modified exendins and uses thereof

Country Status (8)

Country Link
US (1) US8097586B2 (zh)
EP (2) EP1845105A4 (zh)
JP (2) JP4785206B2 (zh)
CN (1) CN100540565C (zh)
CA (1) CA2603630C (zh)
ES (1) ES2541633T3 (zh)
HK (1) HK1095045A1 (zh)
WO (1) WO2006074600A1 (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090318353A1 (en) * 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
WO2008116294A1 (en) * 2007-03-23 2008-10-02 Matregen Corp. Exendin analogs
US8420598B2 (en) 2007-04-20 2013-04-16 B & L Delipharm Corp. Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
US9353170B2 (en) 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
WO2009035540A2 (en) * 2007-09-07 2009-03-19 Ipsen Pharma S.A.S. Analogues of exendin-4 and exendin-3
MX2010008655A (es) * 2008-02-06 2010-10-06 Biocon Ltd Un metodo para purificar un peptido.
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
CN101870728A (zh) * 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
AU2010317995B2 (en) * 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
CN102397558B (zh) * 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Exendin-4类似物的定位聚乙二醇化修饰物及其用途
CN102786590A (zh) * 2011-05-19 2012-11-21 江苏豪森药业股份有限公司 分枝型peg修饰的glp-1类似物及其可药用盐
US20130090285A1 (en) * 2011-06-27 2013-04-11 Phasebio Pharmaceuticals, Inc. Methods of treatment with glp-1 receptor agonists
CN102617728B (zh) * 2012-04-13 2013-07-03 上海交通大学医学院附属瑞金医院 一种Exendin-4的18F标记产物的制备方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
SG11201506804VA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of hydantoin containing peptide products
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
RU2016137264A (ru) * 2014-02-21 2018-03-26 МЕДИММЬЮН, ЭлЭлСи Слияния антитела к pcsk9~glp-1 и способы применения
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
EP3922269A1 (en) * 2016-03-16 2021-12-15 Prolynx LLC Extended release conjugates of exenatide analogs
CN107778361B (zh) * 2016-08-30 2021-07-09 上海交通大学 多肽hl-39及其制备与应用
CN107952064B (zh) * 2016-10-14 2023-10-20 江苏豪森药业集团有限公司 含有聚乙二醇洛塞那肽的药物制剂及其制备方法
CN109929025A (zh) * 2017-12-18 2019-06-25 江苏豪森药业集团有限公司 一种基于反应动力学的聚乙二醇洛塞那肽的制备方法
GB201816639D0 (en) * 2018-10-12 2018-11-28 Heptares Therapeutics Ltd GLP-1 Receptor Antagonist
BR112021008180A2 (pt) 2018-10-30 2021-08-03 Jianning Liu polipeptídeo de glp-1 tendo atividade agonista de receptor glp-1 e uso do mesmo

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118A (en) 1847-05-15 hickok
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
JP2000516912A (ja) * 1996-06-05 2000-12-19 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング エキセンジン類似体、それらの製造方法およびそれらを含有する製剤
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
WO1998043658A1 (en) 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
BR9913857A (pt) 1998-09-17 2001-06-12 Lilly Co Eli Formulações de proteìna
BR0010705A (pt) * 1999-04-30 2002-02-05 Amylin Pharmaceuticals Inc Exendinas modificadas e agonistas da exendina
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
EP1695983B1 (en) 2000-06-16 2009-03-04 Eli Lilly & Company Glucagon-like peptide-1 analogs
WO2003058203A2 (en) 2002-01-08 2003-07-17 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
CA2497794A1 (en) 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
US6969702B2 (en) * 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
DK1620118T3 (da) * 2003-04-08 2014-09-29 Yeda Res & Dev Reversible pegylerede lægemidler

Also Published As

Publication number Publication date
EP2505207A2 (en) 2012-10-03
ES2541633T3 (es) 2015-07-22
US20100009904A1 (en) 2010-01-14
CN1976948A (zh) 2007-06-06
JP4785206B2 (ja) 2011-10-05
CA2603630C (en) 2015-06-09
CN100540565C (zh) 2009-09-16
JP2008526899A (ja) 2008-07-24
WO2006074600A1 (fr) 2006-07-20
EP2505207A3 (en) 2012-11-14
CA2603630A1 (en) 2006-07-20
EP2505207B1 (en) 2015-04-22
JP5528380B2 (ja) 2014-06-25
US8097586B2 (en) 2012-01-17
EP1845105A1 (en) 2007-10-17
JP2011173886A (ja) 2011-09-08
EP1845105A4 (en) 2009-02-18

Similar Documents

Publication Publication Date Title
HK1095045A1 (en) Modified exendins and uses thereof
IL228770A0 (en) processes and intermediates
EP1920216A4 (en) SIGNALING AND LOCATION ORIENTATION
ZA200810323B (en) Fkbp-l and uses thereof
EP1889195A4 (en) PRODUCTION-DESIGN DESIGN AND DESIGNED PRODUCTION
IL184659A0 (en) Antibody variants and uses thereof
PL2064327T3 (pl) Dbait i ich zastosowania
IL179497A0 (en) Carboranylporphyrins and uses thereof
IL185308A0 (en) Replikin peptides and uses thereof
HK1133552A1 (zh) 碳硼烷基卟啉及其用途
IL189252A0 (en) Dihydroxyanthraquinones and their use
EP1912921A4 (en) COMPOUNDS ON TETRAAZAPORPHYRINBASE AND ITS USES
IL180365A0 (en) Carboranylporphyrins and uses thereof
IL185223A0 (en) Compounds and uses thereof
GB0517293D0 (en) Vectors and uses thereof
GB0520935D0 (en) Integrated processor-template-system and project
EP1965829A4 (en) ALTERNATIVE OXIDASE AND ITS USES
GB0516571D0 (en) Novel polypeptides and uses thereof
GB0502978D0 (en) Biomarkers and uses thereof
GB0502843D0 (en) Jig-was and jig-will
GB0522259D0 (en) e-s-spi-l-d-film-cinema-back-engineering armageddon-system and project
GB0517240D0 (en) Chronorotron mk1-system and project
GB0517239D0 (en) Geogrotren-mk1-system and project
GB0517813D0 (en) Peptides and uses thereof
GB0521272D0 (en) Compounds and uses thereof

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: